Research project
HALO study: Haematology Lived Experience and Outcomes
- Start date: 1 October 2023
- End date: 30 September 2026
- Value: £680,000
- Partners and collaborators: Haemoglobinopathy Co-ordinating Centres (HCC) North-East and Yorkshire (NEY), Leeds, Newcastle, Bradford & Sheffield. North-West (NW): Manchester & Liverpool
- Primary investigator: Professor Richard Feltbower
- Co-investigators: Professor Adam Glaser, Dr Kate Absolom, Dr Rubén Mújica-Mota
- External co-investigators: Dr Jacob Grinfeld, Cons Haematologist, LTHT Dr Beki James, Cons Haematologist, LTHT Dr Mike Richards, Cons Haematologist, LTHT Dr Khalid Ahmed, Registrar Haematology Sheffield (ACF)
Description
Funded by Leeds Hospital Charity
HALO is a research study looking at people who were diagnosed with a Sickle Cell Disorder, Beta Thalassemia, acute Lymphoblastic or acute Myeloid Leukaemia in childhood and the long-term effects of that diagnosis and treatment on their life.
• Study aims are
o To identify how these conditions and their treatment might impact on individuals’ long-term health and quality of life.
o Identify unmet needs and health inequalities.
o Use this information to direct where improvements in care and support are needed.
o Highlight how these can improve outcomes.
Other content
Links to Sickle Cell Society; UK Thalassemia Society; Leeds Hospitals Charity; Leeds NIHR BRC
Impact
Forecast: link in with partner organisations and pre-set events in haemoglobinopathy and related calendars to promote study and support engagement